Clinical Trials Using Oncolytic HSV-1 rQNestin34.5v.2

Clinical trials are research studies that involve people. The clinical trials on this list are studying Oncolytic HSV-1 rQNestin34.5v.2. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • rQNestin34.5v.2 with or without Cyclophosphamide in Treating Patients with Recurrent Malignant Glioma

    This phase I clinical trial studies the side effects and best dose of oncolytic HSV-1 rQNestin34.5v.2 (rQNestin34.5v.2) with or without cyclophosphamide in treating patients with malignant glioma that has come back (recurrent). rQNestin34.5v.2 is a drug made from the herpes simplex virus type I, and if it is effective, may spread to a tumor cell, kill it, and then make a copy of itself and spread again. This should be repeated over and over until all tumor cells are reached. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rQNestin34.5v.2 with or without cyclophosphamide may work better in treating patients with recurrent malignant glioma.
    Location: 2 locations